Damora Therapeutics, Inc. Research And Development Expense

• Damora Therapeutics, Inc. showed an increase of +320.1% in Research And Development Expense from 2024 to 2025.
• This data is from Damora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Damora Therapeutics, Inc.'s Research And Development Expense has grown by 36.2%.
• Historical annual values: Fiscal year 2025: $26.88 million | Fiscal year 2024: $6.40 million | Fiscal year 2023: $23.77 million | Fiscal year 2022: $48.21 million | Fiscal year 2021: $38.49 million | Fiscal year 2020: $24.63 million | Fiscal year 2019: $19.74 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026